News

Eisai Laboratorios (Eisai Mexico) initially will focus to establish strategies and an initial infrastructure to support its operations debut into the Mexican market. It is the company’s second

The application was submitted to FDA on the basis of results from a 24-week study assessing 84 patients with central precocious puberty. In the trial, the enrolled patients

The report, ‘Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021,’ says that the market will grow with a CAGR of 8.7% between 2010 and 2016, with finished dosage forms

The AAALAC accreditation insures clients that studies performed at SoBran’s facility will be conducted with the utmost regard for the humane treatment of animals. ISO 9001:2008 certification reflects

The study intends to investigate the safety and efficacy of eteplirsen in DMD patients over 24 weeks of dosing. In the trial, the patients will be given once

The grant will enable Melior to test the usage of a drug currently used in other disease areas for its effects in preclinical models of Parkinson’s disease. MJFF

The funding has been received by The University of Texas Medical Branch (UTMB) in Galveston, which is collaborating with Inviragen to develop the vaccine. Inviragen and UTMB had

The company has posted a net income of $1.77m for the second quarter of 2011, compared to $6.32m for the same period in 2010. Lotus’ income from operations

The drug screen study was designed to assess the anti-cancer activity of the selected compounds using a standard cell proliferation assay procedure, against nine human cancer cell lines.